ImmunoPrecise Antibodies Ltd. (IPA)
- Business Wire
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
VICTORIA, British Columbia, July 23, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) today announces the rescheduling of its full year fiscal 2024 financial results and business highlights release. Originally set for July 25, 2024, the new release date is Monday, July 29, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day.
- Business Wire
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
VICTORIA, British Columbia, July 17, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that it has entered into a securities purchase agreement (the "Securities Purchase Agreement") with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP ("Yorkville"), under which the Company agreed to sell and issue to Yorkville $3.0 million aggregate principal amount of convertible de
- Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
VICTORIA, British Columbia, July 15, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will announce its full year fiscal 2024 financial results and business highlights on Thursday, July 25, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day.
